VRP

VERONA PHARMA PLC ORD 5P

TitleTime
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical ProgramThu 14/05/20 | 07:00
Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR DealingsTue 12/05/20 | 13:11
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International ConferenceFri 01/05/20 | 17:12
Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020Thu 30/04/20 | 07:00
Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate UpdateThu 23/04/20 | 07:00
Verona Pharma plc: Results of AGMThu 16/04/20 | 12:12
Update on AGM ProcedureWed 08/04/20 | 07:00
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPDTue 31/03/20 | 07:00
Verona Pharma plc: Issue of Equity and Total Voting RightsFri 20/03/20 | 11:28
Second Price Monitoring ExtnTue 17/03/20 | 14:06
Price Monitoring ExtensionTue 17/03/20 | 14:01
2019 Annual Report and Accounts and Notice of AGMMon 16/03/20 | 17:13
Grant of Restricted Stock Units and PDMR DealingsThu 05/03/20 | 16:01
Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate UpdateThu 27/02/20 | 07:00
Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate UpdateFri 21/02/20 | 07:00
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory ResearchFri 14/02/20 | 07:00
Holding(s) in Company TR-1: Standard form for notification of major holdingsFri 07/02/20 | 07:00
Verona Pharma Announces Senior Management ChangesMon 03/02/20 | 07:00
Verona Pharma to Present at LSX World Congress 2020Tue 28/01/20 | 07:00
Holding(s) in Company TR-1: Standard form for notification of major holdingsFri 17/01/20 | 13:06
Second Price Monitoring ExtnMon 13/01/20 | 16:41
Price Monitoring ExtensionMon 13/01/20 | 16:35
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium TherapyMon 13/01/20 | 05:00
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium TherapyFri 10/01/20 | 23:00
Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor RelationsTue 07/01/20 | 07:00
Holding(s) in Company TR-1: Standard form for notification of major holdingsThu 28/11/19 | 10:25
Verona Pharma plc: Grant of Options to PDMRWed 27/11/19 | 07:00
Verona Pharma plc: PDMR Dealing ? Purchase by ChairmanMon 18/11/19 | 07:00
Verona Pharma plc: PDMR Dealing ? Purchase by ChairmanThu 14/11/19 | 07:00
Verona Pharma to Present at Jefferies 2019 London Healthcare ConferenceWed 13/11/19 | 07:00
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New YorkMon 11/11/19 | 07:00
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019Tue 05/11/19 | 07:00
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development UpdateTue 29/10/19 | 07:00
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPDThu 17/10/19 | 07:00
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019Tue 15/10/19 | 07:00
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019Thu 19/09/19 | 07:00
Holding(s) in Company TR-1: Standard form for notification of major holdingsMon 09/09/19 | 14:33
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment ConferenceTue 03/09/19 | 07:00
Verona Pharma plc: PDMR DealingFri 09/08/19 | 09:35
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019Tue 06/08/19 | 07:00
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPDMon 05/08/19 | 07:00
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development UpdateTue 30/07/19 | 07:00
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare ConferenceWed 24/07/19 | 07:00
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of EnsifentrineTue 25/06/19 | 07:00
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPDTue 04/06/19 | 07:00
Verona Pharma to Present at Jefferies 2019 Global Healthcare ConferenceThu 30/05/19 | 07:00
PDMR DealingWed 29/05/19 | 11:07
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International ConferenceMon 20/05/19 | 15:15
Result of AGMTue 07/05/19 | 12:51
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 TrialsTue 07/05/19 | 07:00
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019Tue 07/05/19 | 07:00
Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International ConferenceThu 02/05/19 | 12:00
Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development UpdateWed 01/05/19 | 07:00
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK BrokerWed 01/05/19 | 07:00
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019Thu 25/04/19 | 12:07
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate EnsifentrineTue 09/04/19 | 07:00
Grant of Options and RSUs and PDMR DealingsThu 04/04/19 | 07:00
Verona Pharma to Present at H.C. Wainwright Global Life Sciences ConferenceTue 26/03/19 | 07:00
PDMR DealingMon 25/03/19 | 07:00
2018 Annual Report and Accounts and Notice of AGMFri 22/03/19 | 16:00
Dr. Martin Edwards Joins Verona Pharma as Non-Executive DirectorThu 21/03/19 | 07:00
PDMR DealingWed 20/03/19 | 07:00
PDMR DealingMon 11/03/19 | 09:48
PDMR DealingThu 07/03/19 | 08:14
PDMR DealingTue 05/03/19 | 09:48
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPDMon 04/03/19 | 07:00
Verona Pharma to Present at Cowen and Company 39th Annual Health Care ConferenceThu 28/02/19 | 07:00
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development UpdateTue 26/02/19 | 07:00
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development UpdateWed 20/02/19 | 07:00
Verona Pharma to Present at Upcoming Investor ConferencesMon 04/02/19 | 07:00
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance TreatmentMon 14/01/19 | 07:00
Verona Pharma Receives WHO Approval for ?ensifentrine? as Recommended INN for RPL554Wed 09/01/19 | 13:00
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPDMon 17/12/18 | 17:20
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPDMon 17/12/18 | 07:00
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018Tue 06/11/18 | 07:00
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance TreatmentWed 31/10/18 | 07:00
Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development UpdateTue 30/10/18 | 06:00
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma?s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis ConferenceFri 26/10/18 | 10:12
Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018Thu 27/09/18 | 07:00
Issue of Shares & PDMR AnnouncementThu 20/09/18 | 16:49
Verona Pharma to Host Conference Call to Review Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International CongressThu 13/09/18 | 13:00
Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International CongressWed 12/09/18 | 07:00
Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory JournalThu 06/09/18 | 07:00
Verona Pharma plc : PDMR Dealing & Issue of SharesFri 10/08/18 | 12:12
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018Tue 07/08/18 | 07:00
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance TreatmentWed 01/08/18 | 07:00
Verona Pharma plc : Notice of ResultsThu 26/07/18 | 13:30
Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare ConferenceTue 24/07/18 | 13:30
Verona Pharma plc : Result of General Meeting of ShareholdersTue 26/06/18 | 17:22
Verona Pharma's Shelf Registration Statement declared effective by SECMon 04/06/18 | 07:00
Verona Pharma plc : Block Listing UpdateThu 31/05/18 | 07:00
Verona Pharma to Present at Upcoming Investor ConferencesWed 30/05/18 | 13:30
Verona Pharma Files Shelf Registration Statement with SECWed 23/05/18 | 07:00
Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPDTue 22/05/18 | 07:03
Verona Pharma plc : MiscellaneousWed 09/05/18 | 13:30
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018Tue 08/05/18 | 07:00
Verona Pharma to Present at Bio?quity Europe 2018Fri 04/05/18 | 13:30
Verona Pharma plc : Result of AGMThu 03/05/18 | 08:30
Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018Wed 02/05/18 | 13:30
Verona Pharma Announces Departure of Chief Medical OfficerWed 11/04/18 | 07:00
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPDMon 26/03/18 | 07:00
Verona Pharma to Present at Upcoming Healthcare Investor ConferencesThu 15/03/18 | 12:00
Verona Pharma plc: 2017 Annual Report and Accounts and Notice of AGMFri 09/03/18 | 17:30
Verona Pharma plc : Grant of Options and RSUs and PDMR DealingsFri 09/03/18 | 14:24
Verona Pharma plc : 1st Quarter ResultsThu 08/03/18 | 13:38
Second Price Monitoring ExtnFri 02/03/18 | 16:40
Price Monitoring ExtensionFri 02/03/18 | 16:35
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis PatientsFri 02/03/18 | 07:00
Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017Tue 27/02/18 | 07:00
Verona Pharma to Announce Operational Update and Financial Results for Full Year ended December 31, 2017Thu 22/02/18 | 13:45
Verona Pharma Provides Clinical Development UpdateTue 13/02/18 | 12:35
Verona Pharma plc : Block listing Interim ReviewThu 30/11/17 | 18:52
Verona Pharma plc : PDMR DealingThu 30/11/17 | 13:56
Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017Tue 07/11/17 | 07:00
Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentTue 07/11/17 | 07:00
Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017Tue 31/10/17 | 07:00
Verona Pharma to Present at Two Upcoming Investor ConferencesTue 31/10/17 | 06:55
Verona Pharma plc : Total voting rightsMon 02/10/17 | 07:00
Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to PatientsWed 27/09/17 | 07:00
Verona Pharma plc : MiscellaneousTue 19/09/17 | 12:46
Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)Thu 07/09/17 | 07:00
Verona Pharma Appoints Stifel as Nominated AdviserFri 01/09/17 | 07:00
PDMR DealingMon 21/08/17 | 10:41
Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development UpdateTue 08/08/17 | 07:00
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development UpdateWed 02/08/17 | 16:00
Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare ConferenceTue 01/08/17 | 12:05
Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentWed 26/07/17 | 07:00
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across EuropeTue 27/06/17 | 07:00
Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory AffairsThu 22/06/17 | 12:00